HLB Therapeutics Co.,Ltd. (KOSDAQ: 115450)

Market Cap	980.38B
Revenue (ttm)	55.30B
Net Income (ttm)	-28.85B
Shares Out	83.79M
EPS (ttm)	-376.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	388,526
Average Volume	1,059,050
Open	11,700
Previous Close	11,700
Day's Range	11,580 - 11,800
52-Week Range	3,686 - 16,857
Beta	-0.02
RSI	52.09
Earnings Date	Feb 21, 2025

About HLB Therapeutics Co.,Ltd.

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 93
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115450

Financial Performance

In 2023, HLB Therapeutics Co.,Ltd.'s revenue was 53.75 billion, an increase of 26.76% compared to the previous year's 42.40 billion. Losses were -2.30 billion, -79.72% less than in 2022.